Mustang Bio, Inc. has entered into an Asset Purchase Agreement to sell its cell processing facility in Worcester, Massachusetts to uBriGene for a total purchase price of $11 million. The company has also terminated the development of several programs and will reduce its workforce by approximately 82%.